A narrative review of the efficacy and safety of immunotherapy in triple-negative breast cancer: insights from clinical trials and future perspectives

Read full text Summarise with VIRAT
Authors: Bunyese Jenifa Jacob, Xiying Shao, Xiaojia Wang
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background and Objective: Breast cancer was once thought to be unresponsive to immunotherapy but growing insights into the tumor microenvironment (TME) and the development of immune checkpoint inhibitors (ICIs) have changed that perspective. Among all subtypes of breast cancer, triple-negative breast cancer (TNBC) shows the most promising response to immunotherapy, particularly because of its higher expression of programmed death-ligand 1 (PD-L1), higher tumor mutational burden (TMB), and higher levels of tumor-infiltrating lymphocytes (TILs). This narrative review evaluates the efficacy and safety of immunotherapy in TNBC, focusing on ICIs combined with chemotherapy, and the predictive role of biomarkers. Methods: A literature review was conducted using PubMed, Web of Science, Google Scholar, Embase, and ClinicalTrials.gov to search for studies and clinical trials (published between 2017 and 2024) on immunotherapy in TNBC, ICIs, ICIs in combination with chemotherapy, as well as relevant immune biomarkers in TNBC. Key Content and Findings: In early-stage TNBC, KEYNOTE-522 demonstrated that adding pembrolizumab to neoadjuvant chemotherapy and continuing it post-operatively improved the pathological complete response (pCR) and event-free survival (EFS) rates, with benefits seen across all PD-L1 subgroups. In the metastatic setting, the addition of immunotherapy (pembrolizumab in KEYNOTE-355 and atezolizumab in IMpassion130) to chemotherapy significantly improved progression-free survival compared with chemotherapy alone in PD-L1-positive patients. In contrast, IMpassion131 and Keynote-119 showed no survival benefit, suggesting that the efficacy may depend on the specific ICI agent, the chemotherapy drug used, or the patient population. Other trials, such as GeparNuevo, TORCHLIGHT, and NeoTRIP, demonstrated mixed results, with benefits observed only in patients with PD-L1-positive or biomarker-selected tumors. A consistent finding across trials is an increased incidence of immune-related adverse events (irAEs) with the combination of ICI and chemotherapy, though these are generally manageable. Biomarkers such as PD-L1 expression, TILs, and TMB are important for identifying patients most likely to benefit from the treatment. Conclusions: The combination of immunotherapy with chemotherapy brings survival benefits to a subset of TNBC patients, particularly those with suitable biomarkers. However, the associated toxicities and treatment resistance highlight the need for further research to optimize patient selection, improve safety management, and overcome resistance mechanisms.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Breast Cancer Treatment Studies Advanced Breast Cancer Therapies

Publication details

Journal / source
Breast Communications
Volume
2
Pages
3–3
Publication date
1 March 2026
Language
EN